Coagulant Therapeutics

Executive Summary

Coagulant Therapeutics is a private biotechnology company based in Cambridge, MA, founded in 2018. The company focuses on developing novel biologic therapies for acute bleeding, a critical area with limited pharmaceutical options. Its lead program, CT-001, is an engineered recombinant Factor VIIa designed to provide enhanced potency and safety compared to existing treatments. The company leverages deep expertise in the coagulation cascade to address life-threatening hemorrhages, particularly in trauma and surgical settings. While still in early preclinical or clinical stages, CT-001 represents a promising approach to a significant unmet medical need. The company's progress is closely watched by investors interested in hemostasis and emergency medicine.

Upcoming Catalysts (preview)

• Q3 2026IND submission for CT-00170% success
• 2026Series A/B financing or partnership announcement60% success
• H2 2026Preclinical efficacy data release80% success